Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
- PMID: 35267254
- DOI: 10.1097/HRP.0000000000000330
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Abstract
Introduction: First-line treatment for obsessive-compulsive disorder (OCD) includes exposure and response prevention behavioral therapy and serotonin reuptake inhibitors, particularly in combination. New and more effective treatments are needed, give that recent studies suggest that glutamatergic neurotransmission contributes to the pathophysiology of the disorder. In these circumstances, ketamine, as a potent N-methyl-D-aspartate receptor antagonist and glutamate modulator, offers alternative possibilities for OCD treatment.
Methods: This systematic review aims to investigate the effects of ketamine in OCD, following the Preferred Reporting Items for Systematic Review and Meta-analyses Protocols (PRISMA-P). Searches were carried out using the PubMed/MEDLINE, Embase, and PsycINFO databases.
Results: Nine articles were included, of which three were randomized controlled trials, three case reports, two open-label trials, and one a retrospective chart review. Reported data have shown a potential for fast onset of action and good tolerability of ketamine for OCD, even though the principal studies used only single-session racemic ketamine treatments, administered intravenously, and the results have been erratic. In addition, none of the available evidence demonstrates whether racemic ketamine, S-ketamine, or R-ketamine has the best efficacy in controlling OCD symptoms, and only sparse evidence suggests that a combination of ketamine and psychotherapy could benefit patients with OCD.
Conclusion: In order to advance clinical practice regarding the use of ketamine in treating OCD, future randomized, double-blind, placebo-controlled trials are required. These trials need to use larger samples to explore ketamine and its enantiomers, with different methods of administration, multiple sessions, and appropriate washout periods.
Trial registration: ClinicalTrials.gov NCT02624596 NCT01674361.
Copyright © 2022 President and Fellows of Harvard College.
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed.Arlington, VA: APA, 2013.
-
- Shavitt RG, de Mathis MA, Oki F, et al. Phenomenology of OCD: lessons from a large multicenter study and implications for ICD-11. J Psychiatr Res 2014;57:141–8.
-
- Miguel EC, Do Rosário-Campos MC, Da Silva Prado H, et al. Sensory phenomena in obsessive-compulsive disorder and Tourette’s disorder. J Clin Psychiatry 2000;61:150–6.
-
- Sibrava NJ, Boisseau CL, Eisen JL, Mancebo MC, Rasmussen SA. An empirical investigation of incompleteness in a large clinical sample of obsessive compulsive disorder. J Anxiety Disord 2016;42:45–51.
-
- Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011–30.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical